Abstract 541P
Background
Platinum doublet (PtD) plus atezolizumab (ATZ) therapy is one of the standard therapies for advanced NSCLC. However, limited data have been reported for the elderly and patients (pts) with organ dysfunction. Especially, the data for the population aged ≥ 75 years, as defined by the Japan Lung Cancer Society guidelines for NSCLC, and renal dysfunction are insufficient and required. We focused on these points and conducted a post hoc analysis of efficacy and safety using data from two clinical trials.
Methods
The data from two randomized phase 3 clinical trials of PtD plus ATZ, IMpower130 (IM130: carboplatin and nab-paclitaxel with ATZ) and IMpower132 (IM132: carboplatin or cisplatin and pemetrexed with ATZ) were utilized for the integrated analysis. The efficacy and safety were evaluated in pts who were judged to be eligible based on the research protocol and ethics review committee approval. Kaplan-Meier estimates and hazard ratios for PFS and OS were provided.
Results
The subgroup aged ≥ 75 years included 131 pts: 80 pts in the ATZ group (Group A) and 51 pts in the chemotherapy group (Group C) in the integrated population. The median PFS was 8.4 months and 7.1 months (HR=0.59, 95% CI 0.40–0.88), and the median OS was 28.2 months and 15.9 months (HR=0.65, 95% CI 0.39–1.07). The subgroups with Baseline Creatinine Clearance (CCr) of 45 ≤ CCr < 60 mL/min were 57 pts (Group A: 37 pts, Group C: 20 pts) for IM130 and 53 pts (Group A: 28 pts, Group C: 25 pts) for IM132. The PFS and OS for the subgroups were HR=0.46 (95% CI 0.25–0.86) and HR=0.66 (95% CI 0.32–1.37) in IM130 and were HR=0.60 (95% CI 0.32–1.13) and HR=1.12 (95% CI 0.52–2.43) in IM132. Grade ≥ 3 treatment-related adverse events (TRAEs; Groups A and C) were reported in 70.3% and 62.8% of pts ≥ 75 years in the integrated population. In the 45 ≤ CCr < 60 mL/min subgroup in each study, Grade ≥ 3 TRAEs were 78.0% and 42.9% in IM130, and 57.1% and 72.0% in IM132.
Conclusions
The post hoc analysis showed that the combination therapy of PtD and ATZ demonstrated favorable PFS and OS in pts aged ≥ 75 years in the integrated population with tolerable safety. In addition, the combination of carboplatin and nab-paclitaxel with ATZ in IM130 has shown favorable PFS and OS even in pts with renal dysfunction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chugai Pharmaceutical Co., Ltd.
Funding
Chugai Pharmaceutical Co., Ltd.
Disclosure
M. Nishio: Financial Interests, Personal, Speaker, Consultant, Advisor: Ono Pharmaceuticals, Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, Lilly, AstraZeneca, MSD, AbbVie, Takeda, Pfizer, Boehringer Ingelheim, Novartis, Nippon Kayaku, Merck, Janssen. S. Watanabe: Financial Interests, Personal, Research Grant: Boehringer Ingelheim; Financial Interests, Personal, Speaker’s Bureau: Lilly, Pfizer, Novartis Pharma, AstraZeneca, Chugai Pharma, Bristol-Myers, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Nippon Kayaku. H. Udagawa: Financial Interests, Institutional, Funding: Takeda, Boehringer Ingelheim. N. Aragane: Financial Interests, Institutional, Funding: Taiho Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb. H. Saito: Financial Interests, Institutional, Research Grant: Chugai Pharma, AstraZeneca, Ono Pharma, Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharma, AstraZeneca, Ono Pharma, Bristol Myers Squibb, Boehringer Ingelheim, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract